سوق معالجة SJS/TEN في الشرق الأوسط وأفريقيا – اتجاهات الصناعة والتوقعات حتى عام 2030

Request for TOC طلب جدول المحتويات Speak to Analyst تحدث إلى المحلل Buy Now اشتري الآن Inquire Before Buying استفسر قبل Free Sample Report تقرير عينة مجاني

سوق معالجة SJS/TEN في الشرق الأوسط وأفريقيا – اتجاهات الصناعة والتوقعات حتى عام 2030

  • Pharmaceutical
  • Published Report
  • May 2023
  • MEA
  • 350 الصفحات
  • عدد الجداول: 366
  • عدد الأرقام: 55

Middle East And Africa Sjs Ten Treatment Market

حجم السوق بالمليار دولار أمريكي

CAGR :  % Diagram

Diagram فترة التنبؤ
2023 –2030
Diagram حجم السوق (السنة الأساسية)
USD 320.21 Million
Diagram حجم السوق (سنة التنبؤ)
USD 471.24 Million
Diagram CAGR
%
Diagram Major Markets Players
  • Dummy1
  • Dummy2
  • Dummy3
  • Dummy4
  • Dummy5

>سوق علاج SJS/TEN في الشرق الأوسط وأفريقيا، حسب العلاج (الأدوية، الرعاية الداعمة، الاستشفاء، العزل، المراهم وغيرها)، التشخيص (الفحص البدني، خزعة الجلد ، التاريخ الطبي، فحص الدم، الثقافات وغيرها)، السبب (العلاج المحدد، العدوى وغيرها)، طريق الإدارة (عن طريق الفم، والحقن، والموضعي وغيرها)، نوع الدواء (علامة تجارية وعام)، مجال العلاج (العلاج المركب والعلاج الأحادي)، نوع المريض (كبار السن، والبالغين والأطفال)، المستخدم النهائي (المستشفيات، العيادات المتخصصة، مركز الجراحة الخارجية، إعداد الرعاية المنزلية وغيرها)، قناة التوزيع (صيدليات التجزئة، العطاء المباشر وغيرها) - اتجاهات الصناعة والتوقعات حتى عام 2030.

سوق علاج SJS/TEN في الشرق الأوسط وأفريقيا

تحليل ورؤى حول سوق علاج SJS/TEN في الشرق الأوسط وأفريقيا

إن سوق علاج متلازمة ستيفنز جونسون (SJS) وانحلال البشرة السام (TEN) صغير نسبيًا بسبب ندرة هذه الأمراض.

تهيمن الأدوية على سوق علاج SJS/TEN في الشرق الأوسط وأفريقيا، حيث تعد الأدوية الشكل الرئيسي لعلاج هذه الحالات. الكورتيكوستيرويدات، والغلوبولين المناعي الوريدي (IVIG)، والمضادات الحيوية هي الأدوية الأكثر استخدامًا في علاج SJS/TEN.

سوق علاج SJS/TEN في الشرق الأوسط وأفريقياسوق علاج SJS/TEN في الشرق الأوسط وأفريقيا

من المتوقع أن يحقق سوق علاج SJS / TEN في الشرق الأوسط وأفريقيا نموًا في السوق في الفترة المتوقعة من 2023 إلى 2030. تحلل Data Bridge Market Research أن السوق ينمو بمعدل نمو سنوي مركب قدره 5.1٪ في الفترة المتوقعة من 2023 إلى 2030 ومن المتوقع أن يصل إلى 471.24 مليون دولار أمريكي بحلول عام 2030 من 320.21 مليون دولار أمريكي في عام 2022.

يقدم تقرير سوق علاج SJS/TEN في الشرق الأوسط وأفريقيا تفاصيل عن حصة السوق والتطورات الجديدة وتحليل خط أنابيب المنتجات وتأثير اللاعبين المحليين والمحليين في السوق وتحليل الفرص من حيث جيوب الإيرادات الناشئة والتغييرات في لوائح السوق وموافقات المنتجات والقرارات الاستراتيجية وإطلاق المنتجات والتوسعات الجغرافية والابتكارات التكنولوجية في السوق. لفهم التحليل وسيناريو السوق، اتصل بنا للحصول على موجز محلل. سيساعدك فريقنا في إنشاء حل تأثير الإيرادات لتحقيق هدفك المنشود. تعد قابلية التوسع وتوسع أعمال وحدات البيع بالتجزئة في البلدان النامية في مختلف المناطق والشراكة مع الموردين للتوزيع الآمن لمنتجات الآلات والأدوية من المحركات الرئيسية التي دفعت الطلب على السوق في فترة التنبؤ.

تقرير القياس

تفاصيل

فترة التنبؤ

2023 إلى 2030

سنة الأساس

2022

سنوات تاريخية

2021 (قابلة للتخصيص حتى 2015 - 2020)

وحدات كمية

الإيرادات بالملايين من الدولارات الأمريكية

القطاعات المغطاة

Treatment (Medications, Support Care, Hospitalization, Isolation, Ointments, and Others), Diagnosis (Physical Exam, Skin Biopsy, Medical History, Blood Test, Cultures, and Others), Cause (Specific Treatment, Infection, and Others), Route of Administration (Oral, Parenteral, Topical, and Others), Drug Type (Branded and Generic), Therapy Area (Combination Therapy and Monotherapy), Patient Type (Geriatric, Adult, and Paediatric), End User (Hospitals, Specialty Clinics, Ambulatory Surgical Center, Homecare Setting, and Others), Distribution Channel (Retail Pharmacies, Direct Tender, and Others)

Countries Covered

Saudi Arabia,  South Africa, Bahrain, Kuwait, Oman, Qatar, U.A.E., Egypt, Israel, and Rest of Middle East and Africa

Market Players Covered

3M (U.S.), Cardinal Health (U.S.), BD (U.S.), Smith + Nephew (U.K.), Novartis AG (Switzerland), Amneal Pharmaceuticals LLC. (U.S.), Amgen Inc. (U.S.), Pfizer Inc. (U.S.), Colgate-Palmolive Company (U.S.), Merck & Co., Inc. (U.S.), Mölnlycke Health Care AB. (Sweden), Xttrium Laboratories (U.S.), Schülke & Mayr GmbH (Germany), ICPA Health Products Ltd (India), Purdue Pharma L.P. (U.S.), eugia (Subsidiary of Aurobindo Pharma), and AdvaCare Pharma (U.S.) among others 

Market Definition

Stevens-johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are rare but life-threatening skin conditions that usually result from severe drug reactions. These conditions cause the top layer of skin to separate from the layers below, resulting in painful blisters and sores that can cover much of the body. SJS affects a smaller part of the skin, while TEN affects a larger part of the skin.

The definition of the SJS/TEN treatment refers to products and services designed to manage and treat these conditions. There are drugs, therapies, and other treatments in the market that can help relieve SJS/TEN symptoms and improve patients' quality of life.  The drug market for the treatment of SJS/TEN includes a number of drugs that are used to relieve symptoms and treat the underlying cause.

Middle East and Africa SJS/TEN Treatment Market Dynamics

This section deals with understanding the market drivers, advantages, restraints, and challenges. All of this is discussed in detail below:

Drivers

  • Increasing Prevalence and Incidence of SJS/TEN

Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are serious and potentially life-threatening conditions involving the skin and mucous membranes. SJS and TEN are considered two ends of the disease spectrum, with SJS being the milder form and TEN being the more severe form. A characteristic feature of these conditions is the separation of the epidermis (the outer layer of the skin) from the dermis (the layer below the skin) due to a strong immune reaction.

Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are rare but serious skin diseases characterized by the separation of the epidermis from the dermis. The incidence of SJS/TEN has been reported to be around 1 per million people per year. However, in recent years there has been increased concern about the incidence and prevalence of SJS/TEN. 

  • Advances in Drug Development for SJS/TEN Treatment

Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are serious and potentially life-threatening conditions that require prompt and aggressive treatment. Although there is currently no specific medication or treatment that can cure SJS/TEN, advances in drug development have led to better treatment strategies and treatment outcomes for affected patients. But there are various clinical trials going on for drug development for SJS/TEN treatment.

Restraint

  • High Cost Associated With the Treatment of SJS/TEN

One of the main reasons why SJS/TEN treatment is expensive is the need for intensive and long-term treatment. Patients with SJS/TEN often require hospitalization in specialized burn units, where they receive 24-hour care from a team of health professionals including dermatologists, ophthalmologists, and critical care specialists. Hospitalization can last several weeks and in severe cases even months. This can lead to high hospital bills and other related costs such as transportation, accommodation, and meals.

Opportunity

  • Developing Effective and Safe Treatment for SJS/TEN

Stem cell transplantation is a new approach that aims to replace damaged skin and mucous membranes with healthy tissue. Autologous stem cell transplantation, where stem cells are taken from the patient's skin and grown in culture before being transplanted back into the damaged area, has shown promising results in small studies.

Challenge

  • Stringent Government Regulations for Approval of a Treatment for SJS/TEN 

The strict government regulations for the approval of SJS/TEN treatments are related to the complex and rigorous process that pharmaceutical companies and their drugs must go through to obtain approval for an SJS/TEN treatment from regulatory agencies such as the US Food and Drug Administration. (FDA) or the European Medicines Agency (EMA).

The approval process for a new drug usually involves several stages of clinical trials in humans to assess the drug's safety and effectiveness.

Recent Developments

  • In June 2020, BD, a leading Asia-Pacific medical technology company announced that they have completed the acquisition of Straub Medical AG, a privately-held company. With this acquisition, the company has added the valuable expertise and experience of Straub Medical AG and expanded its product portfolio. This will help the company to expand and grow in the market.
  • In January 2019, Mölnlycke Health Care AB. acquires MandJ Airlaid Products A/S to further strengthen its wound care capabilities. In connection with the acquisition, MandJ, and its employees will be an integral part of Mölnlycke. The acquisition will improve Mölnlycke's security of supply for the air-laid material needed to produce advanced wound dressings and help grow the wound care business by accelerating innovation and product development in existing and future products. This will help the company to expand and grow in the market.

Middle East and Africa SJS/TEN treatment market Scope

Middle East and Africa SJS/TEN treatment market is categorized into nine notable segments based on treatment, diagnosis, cause, route of administration, drug type, therapy type, patient type, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

Middle East and Africa SJS/TEN treatment market is categorized into nine notable segments based on treatment, diagnosis, cause, route of administration, drug type, therapy type, patient type, end user, and distribution channel.

Treatment

  • Medications
  • Support Care
  • Ointments
  • Hospitalization
  • Isolation
  • Others

On the basis of treatment, the Middle East and Africa SJS/TEN treatment market is segmented into medications, support care, hospitalization, isolation, ointments, and others.

Diagnosis

  • Physical Exam
  • Medical History
  • Skin Biopsy
  • Blood Test
  • Cultures
  • Others

On the basis of diagnosis, the Middle East and Africa SJS/TEN treatment market is segmented into physical exam, skin biopsy, medical history, blood test, cultures, and others.

Cause

  • Specific Treatment
  • Infection
  • Others

On the basis of cause, the Middle East and Africa SJS/TEN treatment market is segmented into specific treatment, infection, and others.

Route of Administration

  • Oral
  • Parenteral
  • Topical
  • Others

On the basis of route of administration, the Middle East and Africa SJS/TEN treatment market is segmented into oral, parenteral, topical, and others.

Drug Type

  • Branded
  • Generic

On the basis of drug type, the Middle East and Africa SJS/TEN treatment market is segmented into branded and generic.

Therapy Type

  • Monotherapy
  • Combination Therapy

On the basis of therapy type, the Middle East and Africa SJS/TEN treatment market is segmented into combination therapy and monotherapy.

Patient Type

  • Pediatric
  • Adult
  • Geriatric

On the basis of patient type, the Middle East and Africa SJS/TEN treatment market is segmented into geriatric, adult, and pediatric. 

End User

  • Hospitals
  • Specialty Clinics
  • Ambulatory Surgical Center
  • Homecare Setting
  • Others

On the basis of end user, the Middle East and Africa SJS/TEN treatment market is segmented into hospitals, specialty clinics, ambulatory surgical center, homecare setting, and others.

Distribution Channel

  • Direct Tenders
  • Retail Pharmacies
  • Others

على أساس قناة التوزيع، يتم تقسيم سوق علاج SJS/TEN في الشرق الأوسط وأفريقيا إلى صيدليات التجزئة والعطاءات المباشرة وغيرها.

سوق علاج العشرة

تحليل/رؤى إقليمية لسوق علاج SJS/TEN في الشرق الأوسط وأفريقيا

يتم تصنيف سوق علاج SJS/TEN في الشرق الأوسط وأفريقيا إلى تسعة قطاعات بارزة تعتمد على العلاج والتشخيص والسبب وطريق الإدارة ونوع الدواء ونوع العلاج ونوع المريض والمستخدم النهائي وقناة التوزيع.

الدول التي يغطيها تقرير السوق هذا هي المملكة العربية السعودية وجنوب أفريقيا والبحرين والكويت وعمان وقطر والإمارات العربية المتحدة ومصر وإسرائيل وبقية دول الشرق الأوسط وأفريقيا.

ومن المتوقع أن تهيمن جنوب أفريقيا على السوق بفضل التقدم التكنولوجي المتزايد في تطوير الأدوية.

كما يوفر قسم الدولة في التقرير عوامل التأثير الفردية على السوق والتغييرات في التنظيم في السوق محليًا والتي تؤثر على الاتجاهات الحالية والمستقبلية للسوق. تعد نقاط البيانات مثل المبيعات الجديدة ومبيعات الاستبدال والتركيبة السكانية للدولة والقوانين التنظيمية ورسوم الاستيراد والتصدير من بين المؤشرات الرئيسية المستخدمة للتنبؤ بسيناريو السوق للدول الفردية. كما يتم النظر في وجود وتوافر العلامات التجارية في الشرق الأوسط وأفريقيا والتحديات التي تواجهها بسبب المنافسة الكبيرة أو النادرة من العلامات التجارية المحلية والمحلية وتأثير قنوات المبيعات أثناء تقديم تحليل تنبؤي لبيانات الدولة.

تحليل المنافسة وسوق معالجة SJS/TEN في الشرق الأوسط وأفريقيا

يقدم المشهد التنافسي لسوق علاج SJS/TEN في الشرق الأوسط وأفريقيا تفاصيل حسب المنافس. تتضمن التفاصيل نظرة عامة على الشركة، والبيانات المالية للشركة، والإيرادات المتولدة، وإمكانات السوق، والاستثمار في البحث والتطوير، ومبادرات السوق الجديدة، ومواقع الإنتاج والمرافق، ونقاط القوة والضعف في الشركة، وإطلاق المنتج، وموافقات المنتج، وعرض المنتج وتنفسه، وهيمنة التطبيق، ومنحنى شريان الحياة التكنولوجي. ترتبط نقاط البيانات المذكورة أعلاه فقط بتركيز الشركة على سوق علاج SJS/TEN في الشرق الأوسط وأفريقيا.

بعض اللاعبين الرئيسيين العاملين في سوق علاج SJS/TEN في الشرق الأوسط وأفريقيا هم 3M (الولايات المتحدة)، Cardinal Health (الولايات المتحدة)، BD (الولايات المتحدة)، Smith + Nephew (المملكة المتحدة)، Novartis AG (سويسرا)، Amneal Pharmaceuticals LLC. (الولايات المتحدة)، Amgen Inc. (الولايات المتحدة)، Pfizer Inc. (الولايات المتحدة)، Colgate-Palmolive Company (الولايات المتحدة)، Merck & Co.، Inc. (الولايات المتحدة)، Mölnlycke Health Care AB. (السويد)، Xttrium Laboratories (الولايات المتحدة)، Schülke & Mayr GmbH (ألمانيا)، ICPA Health Products Ltd (الهند)، Purdue Pharma LP (الولايات المتحدة)، eugia (شركة تابعة لـ Aurobindo Pharma)، وAdvaCare Pharma (الولايات المتحدة) وغيرها.


SKU-

احصل على إمكانية الوصول عبر الإنترنت إلى التقرير الخاص بأول سحابة استخبارات سوقية في العالم

  • لوحة معلومات تحليل البيانات التفاعلية
  • لوحة معلومات تحليل الشركة للفرص ذات إمكانات النمو العالية
  • إمكانية وصول محلل الأبحاث للتخصيص والاستعلامات
  • تحليل المنافسين باستخدام لوحة معلومات تفاعلية
  • آخر الأخبار والتحديثات وتحليل الاتجاهات
  • استغل قوة تحليل المعايير لتتبع المنافسين بشكل شامل
طلب التجريبي

Table of Content

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF THE MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 TREATMENT LIFELINE CURVE

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.9 DBMR MARKET POSITION GRID

2.1 MARKET APPLICATION COVERAGE GRID

2.11 VENDOR SHARE ANALYSIS

2.12 SECONDARY SOURCES

2.13 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 KEY TRENDS

4.2 COST OF TREATMENT

4.3 KEY PLAYERS STRATEGIES

4.4 LONG TERM GROWTH APPROACH

5 EPIDEMIOLOGY

6 INDUSTRY INSIGHTS

6.1 PATENT ANALYSIS

6.2 DEMOGRAPHIC TRENDS

6.3 PATIENT FLOW DIAGRAM

6.4 KEY PRICING STRATEGIES

6.5 KEY PATIENT ENROLLMENT STRATEGIES

7 MARKET OVERVIEW

7.1 DRIVERS

7.1.1 INCREASING PREVALENCE AND INCIDENCE OF SJS/TEN

7.1.2 ADVANCES IN DRUG DEVELOPMENT FOR SJS/TEN TREATMENT

7.1.3 INCREASING AWARENESS ABOUT THE RARE DISEASE SJS/TEN

7.1.4 GOVERNMENT INITIATIVES FOR SJS/TEN TREATMENT

7.2 RESTRAINTS

7.2.1 HIGH COST ASSOCIATED WITH THE TREATMENT OF SJS/TEN

7.2.2 LIMITED AVAILABILITY OF SPECIALIZED CARE FOR SJS/TEN TREATMENT

7.3 OPPORTUNITIES

7.3.1 DEVELOPING EFFECTIVE AND SAFE TREATMENT FOR SJS/TEN

7.3.2 INCREASING RESEARCH AND DEVELOPMENT ACTIVITIES FOR SJS/TEN TREATMENT

7.4 CHALLENGES

7.4.1 STRINGENT GOVERNMENT REGULATIONS FOR APPROVAL OF TREATMENT FOR SJS/TEN

7.4.2 LONG TERM COMPLICATIONS AND ADVERSE EFFECTS OF MEDICATIONS USED IN THE SJS/TEN TREATMENT

8 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET, BY TREATMENT

8.1 OVERVIEW

8.2 MEDICATIONS

8.2.1 ANTIHISTAMINES

8.2.1.1 HYDROXYZINE

8.2.1.2 FEXOFENADINE

8.2.2 CORTICOSTEROID

8.2.2.1 DEXAMETHASONE

8.2.2.2 PREDNISOLONE

8.2.2.3 METHYLPREDNISOLONE

8.2.2.4 HYDROCORTISONE

8.2.2.5 OTHERS

8.2.3 ANTIBIOTICS

8.2.3.1 NAFCILLIN

8.2.3.2 GENTAMICIN

8.2.3.3 OTHERS

8.2.4 ANALGESICS

8.2.4.1 MORPHINE

8.2.4.2 FENTANYL CITRATE

8.2.4.3 OTHERS

8.2.5 ANTICOAGULANTS

8.2.6 ANTISEPTICS

8.2.6.1 CHLORHEXIDINE GLUCONATE

8.2.6.1.1 PERIOGARD

8.2.6.1.2 PERIDEX

8.2.6.1.3 AVAGARD

8.2.6.1.4 HIBICLENS

8.2.6.1.5 OTHERS

8.2.6.2 OCTENISEPT

8.2.6.3 POLYHEXANIDE SOLUTIONS

8.2.6.4 OTHERS

8.2.7 INTRAVENOUS IMMUNOGLOBULIN

8.2.8 CYCLOSPORINE

8.2.8.1 NEORAL

8.2.8.2 SANDIMMUNE

8.2.8.3 OTHERS

8.2.9 TUMOR NECROSIS FACTOR-ALPHA (TNF-Α)‒BLOCKING AGENT (ETANERCEPT)

8.2.10 OTHER TREATMENT

8.2.10.1 CYCLOPHOSPHAMIDE

8.2.10.2 N-ACETYLCYSTEINE

8.2.10.3 MONOCLONAL ANTIBODIES

8.2.10.4 THALIDOMIDE

8.3 SUPPORT CARE

8.3.1 INTRAVENOUS (IV) FLUID AND ELECTROLYTES

8.3.2 PAIN MANAGEMENT

8.3.2.1 LIDOCAINE

8.3.2.2 OTHERS

8.3.3 NUTRITION SUPPORT

8.3.4 ORAL CARE

8.3.5 PLASMAPHERESIS

8.3.6 BANDAGES

8.3.6.1 BIOLOGICAL DRESSING

8.3.6.1.1 ALLOGRAFT

8.3.6.1.2 XENOGRAFT

8.3.6.1.3 HOMOGRAFT

8.3.6.1.4 OTHERS

8.3.6.2 BIOSYNTHETIC DRESSING

8.3.6.3 SILVER IMPREGNATED DRESSING

8.4 HOSPITALIZATION

8.5 ISOLATION

8.6 OINTMENTS

8.6.1 BENZOCAINE

8.6.2 AMERICAINE

8.6.3 ANBESOL

8.6.4 CHIGGEREX PLUS

8.6.5 OTHERS

8.7 OTHERS

9 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET, BY DIAGNOSIS

9.1 OVERVIEW

9.2 PHYSICAL EXAM

9.3 SKIN BIOPSY

9.4 MEDICAL HISTORY

9.5 BLOOD TEST

9.5.1 COMPLETE BLOOD COUNT

9.5.2 ERYTHROCYTE SEDIMENTATION RATE

9.5.3 COAGULATION STUDIES

9.5.4 UREA AND ELECTROLYTES

9.5.5 LIVER FUNCTION TEST

9.6 CULTURES

9.7 OTHERS

10 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET, BY CAUSE

10.1 OVERVIEW

10.2 SPECIFIC TREATMENT

10.3 INFECTION

10.4 OTHERS

11 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION

11.1 OVERVIEW

11.2 ORAL

11.3 PARENTERAL

11.3.1 INTRAVENOUS

11.3.2 SUBCUTANEOUS

11.3.3 OTHERS

11.4 TOPICAL

11.4.1 OINTMENTS

11.4.2 SOLUTION

11.4.3 CREAMS

11.4.4 OTHERS

11.5 OTHERS

12 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET, BY DRUG TYPE

12.1 OVERVIEW

12.2 BRANDED

12.2.1 NEORAL

12.2.2 SANDIMMUNE

12.2.3 VISTARIL

12.2.4 DURAMORPH

12.2.5 FENTORA

12.2.6 ENBREL

12.2.7 OTHERS

12.3 GENERIC

13 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET, BY THERAPY TYPE

13.1 OVERVIEW

13.2 COMBINATION THERAPY

13.3 MONOTHERAPY

14 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET, BY PATIENT TYPE

14.1 OVERVIEW

14.2 GERIATRIC

14.2.1 FEMALE

14.2.2 MALE

14.3 ADULT

14.3.1 FEMALE

14.3.2 MALE

14.4 PEDIATRIC

15 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET, BY END USER

15.1 OVERVIEW

15.2 HOSPITALS

15.3 SPECIALTY CLINICS

15.4 AMBULATORY SURGICAL CENTER

15.5 HOMECARE SETTING

15.6 OTHERS

16 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL

16.1 OVERVIEW

16.2 RETAIL PHARMACIES

16.2.1 HOSPITAL ASSOCIATED PHARMACIES

16.2.2 DRUG STORE

16.2.3 ONLINE PHARMACIES

16.3 DIRECT TENDERS

16.4 OTHERS

17 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET, BY REGION

17.1 MIDDLE EAST AND AFRICA

17.1.1 SOUTH AFRICA

17.1.2 SAUDI ARABIA

17.1.3 BAHRAIN

17.1.4 U.A.E

17.1.5 KUWAIT

17.1.6 OMAN

17.1.7 QATAR

17.1.8 EGYPT

17.1.9 ISRAEL

17.1.10 REST OF MIDDLE EAST AND AFRICA

18 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET, COMPANY LANDSCAPE

18.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA

19 SWOT ANALYSIS

20 COMPANY PROFILE

20.1 PFIZER INC.

20.1.1 COMPANY SNAPSHOT

20.1.2 REVENUE ANALYSIS

20.1.3 COMPANY SHARE ANALYSIS

20.1.4 PRODUCT PORTFOLIO

20.1.5 RECENT DEVELOPMENT

20.2 NOVARTIS AG

20.2.1 COMPANY SNAPSHOT

20.2.2 REVENUE ANALYSIS

20.2.3 COMPANY SHARE ANALYSIS

20.2.4 PRODUCT PORTFOLIO

20.2.5 RECENT DEVELOPMENT

20.3 MERCK & CO., INC.

20.3.1 COMPANY SNAPSHOT

20.3.2 REVENUE ANALYSIS

20.3.3 COMPANY SHARE ANALYSIS

20.3.4 PRODUCT PORTFOLIO

20.3.5 RECENT DEVELOPMENT

20.4 AMNEAL PHARMACEUTICAL LLC.

20.4.1 COMPANY SNAPSHOT

20.4.2 REVENUE ANALYSIS

20.4.3 COMPANY SHARE ANALYSIS

20.4.4 PRODUCT PORTFOLIO

20.4.5 RECENT DEVELOPMENT

20.5 AMGEN INC.

20.5.1 COMPANY SNAPSHOT

20.5.2 REVENUE ANALYSIS

20.5.3 PRODUCT PORTFOLIO

20.5.4 RECENT DEVELOPMENT

20.6 ADVACARE PHARMA

20.6.1 COMPANY SNAPSHOT

20.6.2 PRODUCT PORTFOLIO

20.6.3 RECENT DEVELOPMENT

20.7 BD

20.7.1 COMPANY SNAPSHOT

20.7.2 REVENUE ANALYSIS

20.7.3 PRODUCT PORTFOLIO

20.7.4 RECENT DEVELOPMENT

20.8 CARDINAL HEALTH

20.8.1 COMPANY SNAPSHOT

20.8.2 REVENUE ANALYSIS

20.8.3 PRODUCT PORTFOLIO

20.8.4 RECENT DEVELOPMENT

20.9 COLGATE-PALMOLIVE COMPANY

20.9.1 COMPANY SNAPSHOT

20.9.2 REVENUE ANALYSIS

20.9.3 PRODUCT PORTFOLIO

20.9.4 RECENT DEVELOPMENT

20.1 EUGIA (SUBSIDIARY OF AUROBINDO PHARMA)

20.10.1 COMPANY SNAPSHOT

20.10.2 REVENUE ANALYSIS

20.10.3 PRODUCT PORTFOLIO

20.10.4 RECENT DEVELOPMENT

20.11 ICPA HEALTH PRODUCTS LTD

20.11.1 COMPANY SNAPSHOT

20.11.2 PRODUCT PORTFOLIO

20.11.3 RECENT DEVELOPMENT

20.12 3M

20.12.1 COMPANY SNAPSHOT

20.12.2 REVENUE ANALYSIS

20.12.3 PRODUCT PORTFOLIO

20.12.4 RECENT DEVELOPMENT

20.13 MOLNLYCKE HEALTH CARE AB.

20.13.1 COMPANY SNAPSHOT

20.13.2 PRODUCT PORTFOLIO

20.13.3 RECENT DEVELOPMENT

20.14 PURDUE PHARMA L.P.

20.14.1 COMPANY SNAPSHOT

20.14.2 PRODUCT PORTFOLIO

20.14.3 RECENT DEVELOPMENT

20.15 SCHULKE & MAYR GMBH

20.15.1 COMPANY SNAPSHOT

20.15.2 PRODUCT PORTFOLIO

20.15.3 RECENT DEVELOPMENT

20.16 SMITH + NEPHEW

20.16.1 COMPANY SNAPSHOT

20.16.2 REVENUE ANALYSIS

20.16.3 PRODUCT PORTFOLIO

20.16.4 RECENT DEVELOPMENT

20.17 XTTRIUM LABORATORIES

20.17.1 COMPANY SNAPSHOT

20.17.2 PRODUCT PORTFOLIO

20.17.3 RECENT DEVELOPMENT

21 QUESTIONNAIRE

22 RELATED REPORTS

List of Table

TABLE 1 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET, PATENT ANALYSIS

TABLE 2 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 3 MIDDLE EAST AND AFRICA MEDICATIONS IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 4 MIDDLE EAST AND AFRICA MEDICATIONS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 5 MIDDLE EAST AND AFRICA ANTIHISTAMINES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 6 MIDDLE EAST AND AFRICA CORTICOSTEROID IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 7 MIDDLE EAST AND AFRICA ANTIBIOTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 8 MIDDLE EAST AND AFRICA ANALGESICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 9 MIDDLE EAST AND AFRICA ANTISEPTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 10 MIDDLE EAST AND AFRICA CHLORHEXIDINE GLUCONATE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 11 MIDDLE EAST AND AFRICA CYCLOSPORINE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 12 MIDDLE EAST AND AFRICA OTHER TREATMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 13 MIDDLE EAST AND AFRICA SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 14 MIDDLE EAST AND AFRICA SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 15 MIDDLE EAST AND AFRICA PAIN MANAGEMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 16 MIDDLE EAST AND AFRICA BANDAGES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 17 MIDDLE EAST AND AFRICA BIOLOGICAL DRESSING IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 18 MIDDLE EAST AND AFRICA HOSPITALIZATION IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 19 MIDDLE EAST AND AFRICA ISOLATION IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 20 MIDDLE EAST AND AFRICA OINTMENTS IN JS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 21 MIDDLE EAST AND AFRICA OINTMENTS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 22 MIDDLE EAST AND AFRICA OTHERS IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 23 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)

TABLE 24 MIDDLE EAST AND AFRICA PHYSICAL EXAM IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 25 MIDDLE EAST AND AFRICA SKIN BIOPSY IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 26 MIDDLE EAST AND AFRICA MEDICAL HISTORY IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 27 MIDDLE EAST AND AFRICA BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 28 MIDDLE EAST AND AFRICA BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 29 MIDDLE EAST AND AFRICA CULTURES IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 30 MIDDLE EAST AND AFRICA OTHERS IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 31 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)

TABLE 32 MIDDLE EAST AND AFRICA SPECIFIC TREATMENT IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 33 MIDDLE EAST AND AFRICA INFECTION IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 34 MIDDLE EAST AND AFRICA OTHERS IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 35 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)

TABLE 36 MIDDLE EAST AND AFRICA ORAL IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 37 MIDDLE EAST AND AFRICA PARENTERAL IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 38 MIDDLE EAST AND AFRICA PARENTERAL IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 39 MIDDLE EAST AND AFRICA TOPICAL IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 40 MIDDLE EAST AND AFRICA TOPICAL IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 41 MIDDLE EAST AND AFRICA OTHERS IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 42 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 43 MIDDLE EAST AND AFRICA BRANDED IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 44 MIDDLE EAST AND AFRICA BRANDED IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 45 MIDDLE EAST AND AFRICA GENERIC IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 46 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)

TABLE 47 MIDDLE EAST AND AFRICA COMBINATION THERAPY IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 48 MIDDLE EAST AND AFRICA MONOTHERAPY IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 49 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)

TABLE 50 MIDDLE EAST AND AFRICA GERAITRIC IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 51 MIDDLE EAST AND AFRICA GERIATRIC IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 52 MIDDLE EAST AND AFRICA ADULT IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 53 MIDDLE EAST AND AFRICA ADULT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 54 MIDDLE EAST AND AFRICA PEDIATRIC IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 55 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 56 MIDDLE EAST AND AFRICA HOSPITALS IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 57 MIDDLE EAST AND AFRICA SPECIALTY CLINICS IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 58 MIDDLE EAST AND AFRICA AMBULATORY SURGICAL CENTER IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 59 MIDDLE EAST AND AFRICA HOMECARE SETTING IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 60 MIDDLE EAST AND AFRICA OTHERS IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 61 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 62 MIDDLE EAST AND AFRICA RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 63 MIDDLE EAST AND AFRICA RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 64 MIDDLE EAST AND AFRICA DIRECT TENDERS IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 65 MIDDLE EAST AND AFRICA OTHERS IN SJS/TEN TREATMENT MARKET, BY REGION, 2021-2030 (USD MILLION)

TABLE 66 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 67 MIDDLE EAST AND AFRICA MEDICATION IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 68 MIDDLE EAST AND AFRICA ANTIHISTAMINES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 69 MIDDLE EAST AND AFRICA CORTICOSTEROID IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 70 MIDDLE EAST AND AFRICA ANTIBIOTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 71 MIDDLE EAST AND AFRICA ANALGESICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 72 MIDDLE EAST AND AFRICA ANTISEPTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 73 MIDDLE EAST AND AFRICA CHLORHEXIDINE GLUCONATE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 74 MIDDLE EAST AND AFRICA CYCLOSPORINE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 75 MIDDLE EAST AND AFRICA OTHER TREATMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 76 MIDDLE EAST AND AFRICA SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 77 MIDDLE EAST AND AFRICA PAIN MANAGEMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 78 MIDDLE EAST AND AFRICA BANDAGES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 79 MIDDLE EAST AND AFRICA BIOLOGICAL DRESSING IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 80 MIDDLE EAST AND AFRICA OINTMENTS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 81 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)

TABLE 82 MIDDLE EAST AND AFRICA BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)

TABLE 83 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)

TABLE 84 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 85 MIDDLE EAST AND AFRICA PARENTERAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 86 MIDDLE EAST AND AFRICA TOPICAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 87 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 88 MIDDLE EAST AND AFRICA BRANDED IN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 89 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET, BY THERAPY AREA, 2021-2030 (USD MILLION)

TABLE 90 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 91 MIDDLE EAST AND AFRICA GERIATRIC IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 92 MIDDLE EAST AND AFRICA ADULT IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 93 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 94 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 95 MIDDLE EAST AND AFRICA RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 96 SOUTH AFRICA SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 97 SOUTH AFRICA MEDICATION IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 98 SOUTH AFRICA ANTIHISTAMINES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 99 SOUTH AFRICA CORTICOSTEROID IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 100 SOUTH AFRICA ANTIBIOTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 101 SOUTH AFRICA ANALGESICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 102 SOUTH AFRICA ANTISEPTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 103 SOUTH AFRICA CHLORHEXIDINE GLUCONATE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 104 SOUTH AFRICA CYCLOSPORINE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 105 SOUTH AFRICA OTHER TREATMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 106 SOUTH AFRICA SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 107 SOUTH AFRICA PAIN MANAGEMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 108 SOUTH AFRICA BANDAGES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 109 SOUTH AFRICA BIOLOGICAL DRESSING IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 110 SOUTH AFRICA OINTMENTS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 111 SOUTH AFRICA SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)

TABLE 112 SOUTH AFRICA BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)

TABLE 113 SOUTH AFRICA SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)

TABLE 114 SOUTH AFRICA SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 115 SOUTH AFRICA PRENTERAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 116 SOUTH AFRICA TOPICAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 117 SOUTH AFRICA SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 118 SOUTH AFRICA BRANDED IN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 119 SOUTH AFRICA SJS/TEN TREATMENT MARKET, BY THERAPY AREA, 2021-2030 (USD MILLION)

TABLE 120 SOUTH AFRICA SJS/TEN TREATMENT MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 121 SOUTH AFRICA GERIATRIC IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 122 SOUTH AFRICA ADULT IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 123 SOUTH AFRICA SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 124 SOUTH AFRICA SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 125 SOUTH AFRICA RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 126 SAUDI ARABIA SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 127 SAUDI ARABIA MEDICATION IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 128 SAUDI ARABIA ANTIHISTAMINES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 129 SAUDI ARABIA CORTICOSTEROID IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 130 SAUDI ARABIA ANTIBIOTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 131 SAUDI ARABIA ANALGESICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 132 SAUDI ARABIA ANTISEPTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 133 SAUDI ARABIA CHLORHEXIDINE GLUCONATE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 134 SAUDI ARABIA CYCLOSPORINE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 135 SAUDI ARABIA OTHER TREATMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 136 SAUDI ARABIA SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 137 SAUDI ARABIA PAIN MANAGEMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 138 SAUDI ARABIA BANDAGES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 139 SAUDI ARABIA BIOLOGICAL DRESSING IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 140 SAUDI ARABIA OINTMENTS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 141 SAUDI ARABIA SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)

TABLE 142 SAUDI ARABIA BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)

TABLE 143 SAUDI ARABIA SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)

TABLE 144 SAUDI ARABIA SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 145 SAUDI ARABIA PARENTERAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 146 SAUDI ARABIA TOPICAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 147 SAUDI ARABIA SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 148 SAUDI ARABIA BRANDED IN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 149 SAUDI ARABIA SJS/TEN TREATMENT MARKET, BY THERAPY AREA, 2021-2030 (USD MILLION)

TABLE 150 SAUDI ARABIA SJS/TEN TREATMENT MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 151 SAUDI ARABIA GERIATRIC IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 152 SAUDI ARABIA ADULT IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 153 SAUDI ARABIA SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 154 SAUDI ARABIA SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 155 SAUDI ARABIA RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 156 BAHRAIN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 157 BAHRAIN MEDICATION IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 158 BAHRAIN ANTIHISTAMINES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 159 BAHRAIN CORTICOSTEROID IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 160 BAHRAIN ANTIBIOTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 161 BAHRAIN ANALGESICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 162 BAHRAIN ANTISEPTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 163 BAHRAIN CHLORHEXIDINE GLUCONATE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 164 BAHRAIN CYCLOSPORINE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 165 BAHRAIN OTHER TREATMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 166 BAHRAIN SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 167 BAHRAIN PAIN MANAGEMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 168 BAHRAIN BANDAGES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 169 BAHRAIN BIOLOGICAL DRESSING IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 170 BAHRAIN OINTMENTS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 171 BAHRAIN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)

TABLE 172 BAHRAIN BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)

TABLE 173 BAHRAIN SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)

TABLE 174 BAHRAIN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 175 BAHRAIN PARENTERAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 176 BAHRAIN TOPICAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 177 BAHRAIN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 178 BAHRAIN BRANDED IN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 179 BAHRAIN SJS/TEN TREATMENT MARKET, BY THERAPY AREA, 2021-2030 (USD MILLION)

TABLE 180 BAHRAIN SJS/TEN TREATMENT MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 181 BAHRAIN GERIATRIC IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 182 BAHRAIN ADULT IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 183 BAHRAIN SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 184 BAHRAIN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 185 BAHRAIN RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 186 U.A.E SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 187 U.A.E MEDICATION IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 188 U.A.E ANTIHISTAMINES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 189 U.A.E CORTICOSTEROID IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 190 U.A.E ANTIBIOTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 191 U.A.E ANALGESICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 192 U.A.E ANTISEPTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 193 U.A.E CHLORHEXIDINE GLUCONATE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 194 U.A.E CYCLOSPORINE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 195 U.A.E OTHER TREATMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 196 U.A.E SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 197 U.A.E PAIN MANAGEMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 198 U.A.E BANDAGES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 199 U.A.E BIOLOGICAL DRESSING IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 200 U.A.E OINTMENTS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 201 U.A.E SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)

TABLE 202 U.A.E BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)

TABLE 203 U.A.E SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)

TABLE 204 U.A.E SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 205 U.A.E PARENTERAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 206 U.A.E TOPICAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 207 U.A.E SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 208 U.A.E BRANDED IN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 209 U.A.E SJS/TEN TREATMENT MARKET, BY THERAPY AREA, 2021-2030 (USD MILLION)

TABLE 210 U.A.E SJS/TEN TREATMENT MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 211 U.A.E GERIATRIC IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 212 U.A.E ADULT IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 213 U.A.E SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 214 U.A.E SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 215 U.A.E RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 216 KUWAIT SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 217 KUWAIT MEDICATION IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 218 KUWAIT ANTIHISTAMINES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 219 KUWAIT CORTICOSTEROID IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 220 KUWAIT ANTIBIOTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 221 KUWAIT ANALGESICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 222 KUWAIT ANTISEPTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 223 KUWAIT CHLORHEXIDINE GLUCONATE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 224 KUWAIT CYCLOSPORINE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 225 KUWAIT OTHER TREATMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 226 KUWAIT SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 227 KUWAIT PAIN MANAGEMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 228 KUWAIT BANDAGES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 229 KUWAIT BIOLOGICAL DRESSING IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 230 KUWAIT OINTMENTS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 231 KUWAIT SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)

TABLE 232 KUWAIT BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)

TABLE 233 KUWAIT SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)

TABLE 234 KUWAIT SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 235 KUWAIT PARENTERAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 236 KUWAIT TOPICAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 237 KUWAIT SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 238 KUWAIT BRANDED IN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 239 KUWAIT SJS/TEN TREATMENT MARKET, BY THERAPY AREA, 2021-2030 (USD MILLION)

TABLE 240 KUWAIT SJS/TEN TREATMENT MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 241 KUWAIT GERIATRIC IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 242 KUWAIT ADULT IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 243 KUWAIT SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 244 KUWAIT SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 245 KUWAIT RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 246 OMAN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 247 OMAN MEDICATION IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 248 OMAN ANTIHISTAMINES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 249 OMAN CORTICOSTEROID IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 250 OMAN ANTIBIOTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 251 OMAN ANALGESICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 252 OMAN ANTISEPTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 253 OMAN CHLORHEXIDINE GLUCONATE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 254 OMAN CYCLOSPORINE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 255 OMAN OTHER TREATMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 256 OMAN SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 257 OMAN PAIN MANAGEMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 258 OMAN BANDAGES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 259 OMAN BIOLOGICAL DRESSING IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 260 OMAN OINTMENTS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 261 OMAN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)

TABLE 262 OMAN BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)

TABLE 263 OMAN SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)

TABLE 264 OMAN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 265 OMAN PARENTERAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 266 OMAN TOPICAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 267 OMAN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 268 OMAN BRANDED IN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 269 OMAN SJS/TEN TREATMENT MARKET, BY THERAPY AREA, 2021-2030 (USD MILLION)

TABLE 270 OMAN SJS/TEN TREATMENT MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 271 OMAN GERIATRIC IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 272 OMAN ADULT IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 273 OMAN SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 274 OMAN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 275 OMAN RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 276 QATAR SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 277 QATAR MEDICATION IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 278 QATAR ANTIHISTAMINES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 279 QATAR CORTICOSTEROID IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 280 QATAR ANTIBIOTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 281 QATAR ANALGESICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 282 QATAR ANTISEPTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 283 QATAR CHLORHEXIDINE GLUCONATE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 284 QATAR CYCLOSPORINE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 285 QATAR OTHER TREATMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 286 QATAR SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 287 QATAR PAIN MANAGEMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 288 QATAR BANDAGES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 289 QATAR BIOLOGICAL DRESSING IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 290 QATAR OINTMENTS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 291 QATAR SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)

TABLE 292 QATAR BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)

TABLE 293 QATAR SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)

TABLE 294 QATAR SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 295 QATAR PARENTERAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 296 QATAR TOPICAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 297 QATAR SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 298 QATAR BRANDED IN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 299 QATAR SJS/TEN TREATMENT MARKET, BY THERAPY AREA, 2021-2030 (USD MILLION)

TABLE 300 QATAR SJS/TEN TREATMENT MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 301 QATAR GERIATRIC IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 302 QATAR ADULT IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 303 QATAR SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 304 QATAR SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 305 QATAR RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 306 EGYPT SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 307 EGYPT MEDICATION IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 308 EGYPT ANTIHISTAMINES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 309 EGYPT CORTICOSTEROID IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 310 EGYPT ANTIBIOTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 311 EGYPT ANALGESICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 312 EGYPT ANTISEPTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 313 EGYPT CHLORHEXIDINE GLUCONATE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 314 EGYPT CYCLOSPORINE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 315 EGYPT OTHER TREATMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 316 EGYPT SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 317 EGYPT PAIN MANAGEMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 318 EGYPT BANDAGES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 319 EGYPT BIOLOGICAL DRESSING IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 320 EGYPT OINTMENTS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 321 EGYPT SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)

TABLE 322 EGYPT BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)

TABLE 323 EGYPT SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)

TABLE 324 EGYPT SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 325 EGYPT PARENTERAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 326 EGYPT TOPICAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 327 EGYPT SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 328 EGYPT BRANDED IN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 329 EGYPT SJS/TEN TREATMENT MARKET, BY THERAPY AREA, 2021-2030 (USD MILLION)

TABLE 330 EGYPT SJS/TEN TREATMENT MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 331 EGYPT GERIATRIC IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 332 EGYPT ADULT IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 333 EGYPT SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 334 EGYPT SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 335 EGYPT RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 336 ISRAEL SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 337 ISRAEL MEDICATION IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 338 ISRAEL ANTIHISTAMINES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 339 ISRAEL CORTICOSTEROID IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 340 ISRAEL ANTIBIOTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 341 ISRAEL ANALGESICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 342 ISRAEL ANTISEPTICS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 343 ISRAEL CHLORHEXIDINE GLUCONATE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 344 ISRAEL CYCLOSPORINE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 345 ISRAEL OTHER TREATMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 346 ISRAEL SUPPORT CARE IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 347 ISRAEL PAIN MANAGEMENT IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 348 ISRAEL BANDAGES IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 349 ISRAEL BIOLOGICAL DRESSING IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 350 ISRAEL OINTMENTS IN SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

TABLE 351 ISRAEL SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)

TABLE 352 ISRAEL BLOOD TEST IN SJS/TEN TREATMENT MARKET, BY DIAGNOSIS, 2021-2030 (USD MILLION)

TABLE 353 ISRAEL SJS/TEN TREATMENT MARKET, BY CAUSE, 2021-2030 (USD MILLION)

TABLE 354 ISRAEL SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 355 ISRAEL PARENTERAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 356 ISRAEL TOPICAL IN SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

TABLE 357 ISRAEL SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 358 ISRAEL BRANDED IN SJS/TEN TREATMENT MARKET, BY DRUG TYPE, 2021-2030 (USD MILLION)

TABLE 359 ISRAEL SJS/TEN TREATMENT MARKET, BY THERAPY AREA, 2021-2030 (USD MILLION)

TABLE 360 ISRAEL SJS/TEN TREATMENT MARKET, BY PATIENT TYPE, 2021-2030 (USD MILLION)

TABLE 361 ISRAEL GERIATRIC IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 362 ISRAEL ADULT IN SJS/TEN TREATMENT MARKET, BY GENDER, 2021-2030 (USD MILLION)

TABLE 363 ISRAEL SJS/TEN TREATMENT MARKET, BY END USER, 2021-2030 (USD MILLION)

TABLE 364 ISRAEL SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 365 ISRAEL RETAIL PHARMACIES IN SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

TABLE 366 REST OF MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD MILLION)

List of Figure

FIGURE 1 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET: SEGMENTATION

FIGURE 2 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET: DATA TRIANGULATION

FIGURE 3 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET: DROC ANALYSIS

FIGURE 4 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET: MIDDLE EAST AND AFRICA VS REGIONAL MARKET ANALYSIS

FIGURE 5 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET: DBMR MARKET POSITION GRID

FIGURE 8 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET: MARKET APPLICATION COVERAGE GRID

FIGURE 9 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET: SEGMENTATION

FIGURE 11 INCREASING PREVALENCE AND INCIDENCE OF SJS/TEN ARE EXPECTED TO DRIVE THE MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET IN THE FORECAST PERIOD FROM 2023 TO 2030

FIGURE 12 THE MEDICATION SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET IN THE FORECAST PERIOD OF 2023 & 2030

FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET

FIGURE 14 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET: BY TREATMENT, 2022

FIGURE 15 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET: BY TREATMENT, 2023-2030 (USD MILLION)

FIGURE 16 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET: BY TREATMENT, CAGR (2023-2030)

FIGURE 17 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET: BY TREATMENT, LIFELINE CURVE

FIGURE 18 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET: BY DIAGNOSIS, 2022

FIGURE 19 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET: BY DIAGNOSIS, 2023-2030 (USD MILLION)

FIGURE 20 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET: BY DIAGNOSIS, CAGR (2023-2030)

FIGURE 21 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET: BY DIAGNOSIS, LIFELINE CURVE

FIGURE 22 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET: BY CAUSE, 2022

FIGURE 23 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET: BY CAUSE, 2023-2030 (USD MILLION)

FIGURE 24 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET: BY CAUSE, CAGR (2023-2030)

FIGURE 25 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET: BY CAUSE, LIFELINE CURVE

FIGURE 26 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2022

FIGURE 27 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2023-2030 (USD MILLION)

FIGURE 28 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2023-2030)

FIGURE 29 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE

FIGURE 30 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET: BY DRUG TYPE, 2022

FIGURE 31 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET: BY DRUG TYPE, 2023-2030 (USD MILLION)

FIGURE 32 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET: BY DRUG TYPE, CAGR (2023-2030)

FIGURE 33 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET: BY DRUG TYPE, LIFELINE CURVE

FIGURE 34 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET: BY THERAPY AREA, 2022

FIGURE 35 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET: BY THERAPY AREA, 2023-2030 (USD MILLION)

FIGURE 36 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET: BY THERAPY AREA, CAGR (2023-2030)

FIGURE 37 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET: BY THERAPY AREA, LIFELINE CURVE

FIGURE 38 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET: BY PATIENT TYPE, 2022

FIGURE 39 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET: BY PATIENT TYPE, 2023-2030 (USD MILLION)

FIGURE 40 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET: BY PATIENT TYPE, CAGR (2023-2030)

FIGURE 41 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET: BY PATIENT TYPE, LIFELINE CURVE

FIGURE 42 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET: BY END USER, 2022

FIGURE 43 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET: BY END USER, 2023-2030 (USD MILLION)

FIGURE 44 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET: BY END USER, CAGR (2023-2030)

FIGURE 45 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET: BY END USER, LIFELINE CURVE

FIGURE 46 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2022

FIGURE 47 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2023-2030 (USD MILLION)

FIGURE 48 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)

FIGURE 49 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 50 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET: SNAPSHOT (2022)

FIGURE 51 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET: BY COUNTRY (2022)

FIGURE 52 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET: BY COUNTRY (2023 & 2030)

FIGURE 53 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET: BY COUNTRY (2022 & 2030)

FIGURE 54 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET: BY TREATMENT (2023-2030)

FIGURE 55 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET: COMPANY SHARE 2022 (%)

View Detailed Information Right Arrow

منهجية البحث

يتم جمع البيانات وتحليل سنة الأساس باستخدام وحدات جمع البيانات ذات أحجام العينات الكبيرة. تتضمن المرحلة الحصول على معلومات السوق أو البيانات ذات الصلة من خلال مصادر واستراتيجيات مختلفة. تتضمن فحص وتخطيط جميع البيانات المكتسبة من الماضي مسبقًا. كما تتضمن فحص التناقضات في المعلومات التي شوهدت عبر مصادر المعلومات المختلفة. يتم تحليل بيانات السوق وتقديرها باستخدام نماذج إحصائية ومتماسكة للسوق. كما أن تحليل حصة السوق وتحليل الاتجاهات الرئيسية هي عوامل النجاح الرئيسية في تقرير السوق. لمعرفة المزيد، يرجى طلب مكالمة محلل أو إرسال استفسارك.

منهجية البحث الرئيسية التي يستخدمها فريق بحث DBMR هي التثليث البيانات والتي تتضمن استخراج البيانات وتحليل تأثير متغيرات البيانات على السوق والتحقق الأولي (من قبل خبراء الصناعة). تتضمن نماذج البيانات شبكة تحديد موقف البائعين، وتحليل خط زمني للسوق، ونظرة عامة على السوق ودليل، وشبكة تحديد موقف الشركة، وتحليل براءات الاختراع، وتحليل التسعير، وتحليل حصة الشركة في السوق، ومعايير القياس، وتحليل حصة البائعين على المستوى العالمي مقابل الإقليمي. لمعرفة المزيد عن منهجية البحث، أرسل استفسارًا للتحدث إلى خبراء الصناعة لدينا.

التخصيص متاح

تعد Data Bridge Market Research رائدة في مجال البحوث التكوينية المتقدمة. ونحن نفخر بخدمة عملائنا الحاليين والجدد بالبيانات والتحليلات التي تتطابق مع هدفهم. ويمكن تخصيص التقرير ليشمل تحليل اتجاه الأسعار للعلامات التجارية المستهدفة وفهم السوق في بلدان إضافية (اطلب قائمة البلدان)، وبيانات نتائج التجارب السريرية، ومراجعة الأدبيات، وتحليل السوق المجدد وقاعدة المنتج. ويمكن تحليل تحليل السوق للمنافسين المستهدفين من التحليل القائم على التكنولوجيا إلى استراتيجيات محفظة السوق. ويمكننا إضافة عدد كبير من المنافسين الذين تحتاج إلى بيانات عنهم بالتنسيق وأسلوب البيانات الذي تبحث عنه. ويمكن لفريق المحللين لدينا أيضًا تزويدك بالبيانات في ملفات Excel الخام أو جداول البيانات المحورية (كتاب الحقائق) أو مساعدتك في إنشاء عروض تقديمية من مجموعات البيانات المتوفرة في التقرير.

Frequently Asked Questions

The Middle East and Africa SJS/TEN Treatment Market is projected to grow at a CAGR of 5.1% during the forecast period by 2030.
The future market value of the Middle East and Africa SJS/TEN Treatment Market is expected to reach USD 471.24 million by 2030.
The major players in the Middle East and Africa SJS/TEN Treatment Market are 3M (U.S.), Cardinal Health (U.S.), BD (U.S.), Smith + Nephew (U.K.), Novartis AG (Switzerland), Amneal Pharmaceuticals LLC. (U.S.), Amgen Inc. (U.S.), Pfizer Inc. (U.S.), Colgate-Palmolive Company (U.S.), etc.
The countries covered in the Middle East and Africa SJS/TEN Treatment Market are Saudi Arabia, South Africa, Bahrain, Kuwait, Oman, Qatar, U.A.E., Egypt, Israel, and Rest of Middle East and Africa.